Abstract
Prion diseases display multiple disease phenotypes characterized by diverse clinical symptoms, different brain regions affected by the disease, distinct cell tropism and diverse PrPSc deposition patterns. The diversity of disease phenotypes within the same host is attributed to the ability of PrPC to acquire multiple, alternative, conformationally distinct, self-replicating PrPSc states referred to as prion strains or subtypes. Structural diversity of PrPSc strains has been well documented, yet the question of how different PrPSc structures elicit multiple disease phenotypes remains poorly understood. The current article reviews emerging evidence suggesting that carbohydrates in the form of sialylated N-linked glycans, which are a constitutive part of PrPSc, are important players in defining strain-specific structures and disease phenotypes. This article introduces a new hypothesis, according to which individual strain-specific PrPSc structures govern selection of PrPC sialoglycoforms that form strain-specific patterns of carbohydrate epitopes on PrPSc surface and contribute to defining the disease phenotype and outcomes.
Keywords: prions, prion disease, prion strains, N-linked glycans, glycosylation, sialic acid, sialylation
1. Introduction
Prion diseases or transmissible spongiform encephalopathies represent a class of lethal, transmissible neurodegenerative disorders of humans and animals [1,2]. Prions or PrPSc are proteinaceous infectious agents that consist of misfolded, self-replicating states of a sialoglycoprotein called the prion protein or PrPC. Prions spread between organisms or from cell to cell by recruiting host-encoded PrPC and replicating their disease-specific misfolded structures via a template-assisted mechanism [3]. Prion diseases display multiple disease phenotypes characterized by diverse clinical symptoms, different brain regions affected by the disease, distinct cell tropism and diverse PrPSc deposition patterns [4]. The diversity of disease phenotypes within the same host is attributed to the ability of PrPC to acquire multiple, alternative, conformationally distinct, self-replicating PrPSc states referred to as prion strains or subtypes [5,6,7,8,9,10]. Structural diversity of PrPSc strains has been well documented [11,12,13], yet the question of how different PrPSc structures elicit multiple disease phenotypes remains poorly understood.
PrPC is post-translationally modified with a glycophosphatidylinositol (GPI) anchor and up to two N-linked glycans [14,15,16,17]. These modifications are carried over upon conversion of PrPC into PrPSc [14,16,17,18,19]. PrPC expressed in a cell exhibit astonishing heterogeneity, which is attributed to variations in the structure and composition of N-glycans with more than 400 different PrPC glycoforms described [19,20,21]. Because each of the two N-glycans can carry up to five and possibly even more negatively charged sialic acid residues [19,20,21], PrPC molecules also display a dramatic range of pIs or net charges at physiological pH [22,23]. Considering their bulky size, a broad range of negative charges and extreme structural heterogeneity, we were interested to learn whether N-glycans played a role in defining strain-specific PrPSc structural and pathological features.
2. N-glycans Are Exposed on a Surface of PrPSc
Molecular models of PrPSc particles proposed in the past assumed that the N-glycans are directed outwards [24,25,26] exposing terminal sialic acid residues on the surface of PrPSc particles. For testing whether N-glycans are indeed directed outwards of PrPSc particles, brain slices from scrapie-infected animals were stained using Sambucus Nigra lectin (SNA). Animals infected with the S05 strain were selected, as this strain is characterized by deposition of large PrPSc plaques [27,28]. In PrPC and PrPSc, sialic acid residues are attached to galactose via α2-3 or α2-6 linkages with the majority being linked via α2-6 [20,21,29]. SNA lectin was used for staining, because of its specificity for sialic acid residues attached via α2-6 linkages. As expected, PrPSc plaques showed intense staining with SNA (Figure 1A–D). In fact, higher intensity of PrPSc staining relative to that of the brain sialoglycocalix suggests that the density of sialylation on PrPSc surface exceeds that of sialoglycocalyx. This result is consistent with the previous study that report intense staining of PrPSc plaques by Alcian Blue, a polyvalent basic dye which is used for staining of sialylated glycocalyx [30]. High intensity of straining with both SNA and Alcian Blue illustrate a high density of sialylation on PrPSc surface.
3. Structural Constraints Imposed by N-glycans
Several structures that exhibit diverse PrP folding patterns have been considered in recent years to model the structure of PrPSc (reviewed in [26]). They include parallel in-register β-structure and two-, three- or four-rung β-solenoids [25,31,32,33,34]. To build a realistic molecular model of PrPSc, our knowledge about PrPSc glycosylation status, size of the glycans and their charge should be considered. Which of the proposed models can accommodate N-linked glycans?
For addressing this question, a tri-antennary glycan with a size average of those found in PrP sialoglycoforms was used for modeling PrPSc [35]. In in-register parallel β-sheet structure, the glycans of neighboring PrP molecules have to be spaced at a distance of 4.7 Å that brings them into substantial spatial interference that precludes such arrangements [35]. Considerable spatial overlap between glycans still exists in a two-rung solenoid that separates glycans at a distance of 2 × 4.7 Å [35]. However, three-rung solenoids permit recruitment with minimal interference, whereas four-rung solenoid can accommodate diglycosylated PrP molecules without interference [35]. This modeling supports the hypothesis that N-glycans limit the diversity of folding patterns accessible to glycosylated PrPC.
4. Two Alternative Views on Involvement of N-glycans
Prion strains display strain-specific ratios of di-, mono- and unglycosylated glycoforms, which are often considered to be among the features defining strain. identity (reviewed in [36]). Toward answering the question of whether glycans are important in defining strain-specific PrPSc structures, two alternative views could be taken into consideration. According to one view, prion strains can partially overcome constraints imposed by glycans by selectively recruiting mono- and un-glycosylated PrPC glycoforms at the expense of diglycosylated glycoforms. Only those PrPC glycoforms could be successfully recruited that fit into strain-specific PrPSc structures. An alternative view proposes that recruitment is not selective; glycoforms are recruited proportionally to their relative representations in a pool of PrPC molecules. If this is the case, the spectrum of PrPSc structures would be limited to those that can accommodate a high percentage of diglycosylated glycoforms, since diglycosylated glycoforms dominate the pool of PrPC molecules.
To answer the question of whether prion strains recruit PrPC sialoglycoforms selectively, we analyze the composition of sialoglycoforms within PrPSc using 2D gels [37,38]. Because N-linked glycans carry negatively charged sialic acid residues, the sialoglycoforms can be separated in a horizontal dimension of 2D according to their charge [35,39]. For the 2D, PrPSc was denatured into monomers first, and then monomers were separated according to their sialylation status in horizontal dimension and their glycosylation status in vertical dimension. Then, 2D analysis of multiple strains from two hosts revealed that PrPSc strains exhibit a broad range of strain-specific selectivity with respect to PrPC sialoglycoforms (Figure 2) [37]. Consistent with the first view, a group of strains shows strong preferences, as they excluded highly sialylated molecules as well as diglycosylated molecules (Figure 2, represented by strain #2). At the same time, in support of the second view, a group of strains did not display any preferences with respect to glycosylation or sialylation status (Figure 2, represented by strain #1). In addition, atypical PrPSc of synthetic origin was highly selective [28,40], as it excluded most of the diglycosylated and also highly and moderately sialylated PrPC molecules (Figure 2, strain #3).
Analysis across all strains examined revealed a great correlation between the glycosylation and sialylation status within PrPSc (Figure 3) [37]. This analysis also demonstrated a broad range of selectivity displayed by prion strains in recruiting PrPC sialoglycoforms, ranging from non-selective to highly selective (Figure 3). Notably, for the group of non-selective strains, the composition of sialoglycoforms within PrPSc was very similar to that of PrPC.
5. Relationship between Strain-Specific Structure and Selectivity for PrPC Sialoglycoforms
Here we propose that a broad range of selectivity with respect to recruiting PrPC sialoglycoforms expressed by prion strains could be attributed to strain-specific variations in quaternary structure (i.e., assembly of PrP monomers into multimers within PrPSc) and achieved in the absence of significant strain-specific variations in folding pattern. Specifically, we propose that for non-selective strains, there is a considerable twist or rotation between neighboring PrP molecules assembled in PrPSc particles (Figure 4). Owing to such rotations, glycans extend into different directions avoiding spatial interference and minimizing electrostatic repulsion between their sialic acid residues. In strains that select against diglycosylated and highly sialylated PrPC, the twist between neighboring PrP molecules is very small or absent (Figure 4). As a result, such a mode of assembly creates spatial and electrostatic interference between glycans limiting recruitment of diglycosylated and highly sialylated PrPC. The three- or four-rung solenoid models offer the best opportunity for accommodating both selective and non-selective strains. The proposed arrangement of N-linked glycans and sialic acid residues in selective and non-selective strains (Figure 4) could be used to distinguish these strains experimentally, based on their ultrastructure or fibril morphology. If our hypothesis is correct, non-selective strains are expected to display twisted fibril morphologies, whereas selective strains should show less twisted or non-twisted morphologies.
Previous studies employed differentially glycosylated PrPC molecules and Protein Misfolding Cyclic Amplification (PMCA) to explore the role of N-linked glycans in prion replication [41]. Consistent with the model presented in Figure 4, unglycosylated PrPC molecules were required for propagating the RML strain [41], which belongs to the group of selective strains (Figure 3). Propagation of the Sc237 strain, which has the same origin as the 263K stain and presumably belongs to the group of non-selective strains (Figure 3), relied on diglycosylated PrPC molecules [41]. The fact that diglycosylated PrPC molecules were required for replication of the Sc237 strain suggests that N-linked glycans might play a role in stabilizing multimeric structures of non-selective strains via intermolecular interactions.
6. Role of N-glycans in Maintaining High Fidelity of Prion Replication
Prions replicate with high fidelity when transmitted within the same host. Do N-glycans play a role in preserving high fidelity of prion replication? Considering that N-glycans limit diversity of folding patterns accessible to PrPC, removal of PrPC glycans is expected to impair fidelity of replication. Eliminating the entire glycans from donor PrPSc did not affect strain-specific neurotropism upon transmission of two strains, RML or 301C, to wild type host with unaltered glycosylation status of PrPC [42]. However, this was not the case when glycosylation status of PrPC expressed by a host was altered. Transmission of prions to hosts expressing PrPC deficient in one or both N-glycans was found to change strain-specific characteristics of the 79A strain, yet did not affect considerably strain-specific properties of ME7 or 301C [43]. Moreover, glycosylation of the host PrPC was found to have a significant impact on the transmission of prions between different species [44]. These studies support the view that loss of structural constraints imposed by PrPC glycans might indeed impair fidelity of prion replication to the extent that, in some cases, result in changes of strain properties and disease phenotype.
7. Role of Sialic Acid Residues and Electrostatic Repulsions in Prion Replication/Strain-Specific Properties
Assuming that PrPSc adapts three- or four-rung solenoid folding patterns, sialylation of N-linked glycans would result in a highly dense negative charge on PrPSc surface (Figure 5). Does electrostatic repulsion between sialic acid residues impose constraints on PrPSc surfaces that affects prion replication rate? If electrostatic repulsion is indeed substantial, one might expect that removing sialic acid residues from PrPC should facilitate PrPC recruitment and accelerate replication rates of PrPSc. For testing whether this is the case, amplification rates of several prion strains were examined using PMCA conducted in PrPC substrate desialylated by neuraminidase treatment, and in normal non-treated substrates [22,37]. As predicted by the above hypothesis, a significant increase in replication rates was observed in desialylated relative to normal substrates for all strains tested [22,37]. Moreover, an increase in replication rates was found to be strain-specific ranging from 10-fold to ~ 106-fold [22,37]. The fact that removing sialic acids boosts replication rates in a strain-specific manner suggests that PrPSc surfaces are decorated by sialic acid in strain-specific patterns generating strain-specific density of negative charges.
As discussed above, a strain-specific glycoform ratio is a result of negative selection of diglycosylated sialoglycoforms carrying bulky, highly charged glycans. Is it electrostatic repulsion between sialic acid residues or spatial interference between bulky glycans that imposes constraints and limits recruitment of diglycosylated glycforms? To answer this question, glycoform ratios were analyzed in PrPSc generated from desialylated substrate in PMCA. In PMCA-derived PrPSc produced from desialylated substrate, the relative ratio of glycoforms shifted to predominantly diglycosylated regardless of the glycosylation status of strains used for seeding [37]. In fact, upon replication in desialylated substrate, prion strains lost their strain-specific glycoform ratios that become very similar to the glycoform ratio of PrPC [37]. In summary, these experiments revealed that negative selection of diglycosylated glycoforms is abolished, when sialic acid residues are removed. As such, the sialylation level appears to be even more important than the size of glycans in imposing constraints and defining strain-specific glycoform ratios.
8. Surface Carbohydrate Epitopes of PrPSc as Molecular Cues for CNS
Under a normal replication environment, prion strains maintain their strain-specific ratios of glycoforms that range from predominantly un- and mono-glycosylated to highly diglycosylated (reviewed in [36]). Differences in glycosylation status, which is presumably attributed to strain-specific structural constraints, suggest that each strain can accommodate only a certain number of sialylic acid residues per PrP molecule on PrPSc surface yielding a strain-specific density of negative charges. Moreover, as a result of selective recruitment, each strain is likely to display an individual, strain-specific pattern of carbohydrate epitopes on PrPSc surface. One might speculate that strain-specific patterns of carbohydrate epitopes will define the range of potential PrPSc-binding partners interacting with PrPSc giving rise to individual, strain-specific biological features. Several protein families including siglecs, selectins, galectins, complement system components, mannose receptors and asialoglycoprotein receptors recognize carbohydrate groups and are involved in an innate immune response [46,47]. Because the majority of carbohydrate-binding molecules have multivalent binding sites, the strength and selectivity of binding is not only dependent on the composition of functional carbohydrate epitopes but also on their density and specific configuration of carbohydrate groups.
Below, we discuss specific examples illustrating involvement of carbohydrate epitopes on PrPSc surface in triggering CNS response and determining the fate of prions (Figure 6). Our recent studies revealed that desialylation of N-linked glycans of PrPSc undermines survival of prions in vivo. On the surface of a mammalian cell, sialoglycocalyx acts as a part of a “self-associated molecular pattern” helping the innate immune system to recognize “self” from “altered self” or “non-self” [48,49]. Removal of sialic acids from cell surface glycans exposes galactose residues that generate “eat me” signals for professional and non-professional macrophages, for example, stimulating clearance of erythrocytes or platelets by Kupffer cells [50,51], or phagocytosis of neurons by microglia [52,53,54]. Maintaining sufficient sialylation levels appears to be as important for prion survival as it is for preserving healthy mammalian cells (Figure 6A,B). Our recent studies demonstrated that donor PrPSc with reduced sialylation levels did not induce prion disease in animals after intracranial or intraperitoneal inoculations [22,55,56] (Figure 6A,B). Moreover, animals inoculated with PrPSc with reduced sialylation levels were found to be free of prions for their life-time [55,56]. Upon peripheral exposure, prions are known to be first uptaken by dendritic cells, monocytes and B lymphocytes [57,58], which spread prions through the body before they are sequestered by secondary lymphoid organs (SLOs) [59,60,61,62]. Prions replicate and are accumulated in SLOs prior to their invasion of CNS [59,60,61,62,63,64]. Sialylation of PrPSc was found to be critical for its trafficking and colonization of SLOs [56]. PrPSc with reduced sialylation was found in the liver instead of SLOs. Yet, PrPSc that colonizes SLOs was shown to be subject to enhanced post-conversion sialylation, a process that might provide extra protection from the innate immune system [38]. These studies suggested that sialylation protects PrPSc against clearance and appears to be critical in defining the fate of prion infection. Consistent with this hypothesis, our recent work revealed that PrPSc can directly trigger proinflammatory response in microglia with a degree of response found to be determined by the degree of sialylation of PrPSc [65].
Another example that might shed light on the relationship between PrPSc molecular features and neuroinflammation deals with a unique PrPSc-like state that has substantially reduced both glycosylation and sialylation levels (will be referred to as atypical PrPSc) [27,40,66]. Atypical PrPSc is a self-replicating transmissible state [28,67,68], which accumulates in the form of small synaptic deposits and large plaques [66]. Yet, it is a clinically silent state that does not cause neuronal death, pathological lesions or any detectible clinical signs of the prion diseases [27,28,40,66,67]. Remarkably, atypical PrPSc recruits mono- and un-glycosylated PrPC of a host, while strongly excluding di-glycosylated and sialylated PrPC molecules [28] (strain #3 in Figure 2, and Figure 3). In fact, out of ten strains tested, atypical PrPSc had the lowest glycosylation and sialylation status [28,37]. Staining with SNA confirmed that sialylation levels of atypical PrPSc is significantly lower relative to those of conventional PrPSc or brain sialoglycocalyx (Figure 1E,F). Yet, unlike desialylated PrPSc, atypical PrPSc does not expose terminal galactose at high density, which is considered to be an “eat me” signal (Figure 6). As a result, it replicates and accumulates steadily in CNS. Atypical PrPSc lacks toxicity and does not case neuroinflammation [66], features that appear to be attributed to its unique glycosylation and sialylation status.
9. Concluding Remarks
N-glycans are exposed on the PrPSc surface and impose considerable structural constraints to PrPSc assembly due to their bulky size and electrostatic repulsion between sialic acid residues. To overcome these restraints, prion strains exhibit a wide range of selectivity in recruiting PrPC sialoglycoforms. While some strains recruit sialoglycoforms proportionally to their representation in PrPC, others avoid diglycosylated and highly sialylated PrPC glycofoms. We propose that strain-specific selectivity in recruiting PrPC sialoglycoforms reports on strain-specific differences in PrPSc quaternary structures and has to be taken into consideration when building realistic PrPSc models. Moreover, we hypothesize that as a result of strain-specific selection, N-linked glycans form individual strain-specific patterns of functional carbohydrate epitopes on PrPSc surfaces and elicit strain-specific responses in CNS. It has been well established that the innate immune system senses terminal carbohydrate groups including galactose and sialic acid residues, which can serve as molecular cues and trigger diverse response programs by glia. Consistent with previous studies on self-associated and pathogen-associated molecular patterns, our work revealed that desialylation of PrPSc undermines survival of prions in vivo. At the same time, recruiting PrPC with low sialylation levels speeds up PrPSc replication, which could be beneficial to prion spread. Therefore, evolution of prion strains might represent a delicate balance between recruiting of highly sialylated glycoforms and generating sufficient density of sialylation for avoiding an “eat-me” response by glia, yet limiting extremely heavily sialylated glycoforms for enabling efficient prion replication. It remains to be tested in future studies whether carbohydrate epitopes on PrPSc surface trigger responses in the CNS in a strain-specific manner.
Author Contributions
N.M. performed staining of brains presented in Figure 1; E.K. generated the models presented in Figure 4 and Figure 5; I.V.B. wrote the manuscript; all authors provided feedback and approved the manuscript.
Funding
Financial support for this study was provided by National Institute of Health Grants R01 NS045585 and R01 AI128925.
Conflicts of Interest
The authors declare no conflict of interest.
References
- 1.Prusiner S.B. Novel proteinaceous infectious particles cause scrapie. Science. 1982;216:136–144. doi: 10.1126/science.6801762. [DOI] [PubMed] [Google Scholar]
- 2.Legname G., Baskakov I.V., Nguyen H.O.B., Riesner D., Cohen F.E., DeArmond S.J., Prusiner S.B. Synthetic mammalian prions. Science. 2004;305:673–676. doi: 10.1126/science.1100195. [DOI] [PubMed] [Google Scholar]
- 3.Cohen F.E., Prusiner S.B. Pathologic conformations of prion proteins. Annu. Rev. Biochem. 1998;67:793–819. doi: 10.1146/annurev.biochem.67.1.793. [DOI] [PubMed] [Google Scholar]
- 4.Collinge J., Clarke A.R. A General Model of Prion Strains and Their Pathogenicity. Science. 2007;318:930–936. doi: 10.1126/science.1138718. [DOI] [PubMed] [Google Scholar]
- 5.Bessen R.A., Marsh R.F. Identification of two biologically distinct strains of transmissible mink encephalopathy in hamsters. J. Gen. Virol. 1992;73:329–334. doi: 10.1099/0022-1317-73-2-329. [DOI] [PubMed] [Google Scholar]
- 6.Peretz D., Scott M., Groth D., Williamson A., Burton D., Cohen F.E., Prusiner S.B. Strain-specified relative conformational stability of the scrapie prion protein. Protein Sci. 2001;10:854–863. doi: 10.1110/ps.39201. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Safar J., Wille H., Itri V., Groth D., Serban H., Torchia M., Cohen F.E., Prusiner S.B. Eight prion strains have PrP Sc molecules with different conformations. Nat. Med. 1998;4:1157–1165. doi: 10.1038/2654. [DOI] [PubMed] [Google Scholar]
- 8.Ayers J.L., Schutt C.R., Shikiya R.A., Aguzzi A., Kincaid A.E., Bartz J.C. The strain-encoded relationship between PrP replication, stability and processing in neurons is predictive of the incubation period of disease. PLoS Pathog. 2011;7:e1001317. doi: 10.1371/journal.ppat.1001317. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Gonzalez-Montalban N., Makarava N., Savtchenko R., Baskakov I.V. Relationship between Conformational Stability and Amplification Efficiency of Prions. Biochemistry. 2011;50:7933–7940. doi: 10.1021/bi200950v. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Klimova N., Makarava N., Baskakov I.V. The diversity and relationship of prion protein self-replicating states. Virus Res. 2015;207:113–119. doi: 10.1016/j.virusres.2014.10.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Caughey B., Raymond G.J., Bessen R.A. Strain-dependent differences in b-sheet conformations of abnormal prion protein. J. Biol. Chem. 1998;273:32230–32235. doi: 10.1074/jbc.273.48.32230. [DOI] [PubMed] [Google Scholar]
- 12.Spassov S., Beekes M., Naumann D. Structural differences between TSEs strains investigated by FT-IR spectroscopy. Biochim. Biophys. Acta. 2006;1760:1138–1149. doi: 10.1016/j.bbagen.2006.02.018. [DOI] [PubMed] [Google Scholar]
- 13.Thomzig A., Spassov S., Friedrich M., Naumann D., Beekes M. Discriminating Scrapie and Bovine Spongiform Encephalopathy Isolates by Infrared Spectroscopy of Pathological Prion Protein. J. Biol. Chem. 2004;279:33847–33854. doi: 10.1074/jbc.M403730200. [DOI] [PubMed] [Google Scholar]
- 14.Stahl N., Borchelt D.R., Hsiao K., Prusiner S.B. Scrapie prion protein contains a phosphatidylinositol glycolipid. Cell. 1987;51:229–240. doi: 10.1016/0092-8674(87)90150-4. [DOI] [PubMed] [Google Scholar]
- 15.Bolton D.C., Meyer R.K., Prusiner S.B. Scrapie PrP 27-30 is a sialoglycoprotein. J. Virol. 1985;53:596–606. doi: 10.1128/jvi.53.2.596-606.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Turk E., Teplow D.B., Hood L.E., Prusiner S.B. Purification and properties of the cellular and scrapie hamster prion proteins. Eur. J. Biochem. 1988;176:21–30. doi: 10.1111/j.1432-1033.1988.tb14246.x. [DOI] [PubMed] [Google Scholar]
- 17.Stahl N., Baldwin M.A., Teplow D.B., Hood L., Gibson B.W., Burlingame A.L., Prusiner S.B. Structural studies of the scrapie prion protein using mass spectrometry and amino acid sequencing. Biochemistry. 1993;32:1991–2002. doi: 10.1021/bi00059a016. [DOI] [PubMed] [Google Scholar]
- 18.Stahl N., Baldwin M.A., Hecker R., Pan K.M., Burlingame A.L., Prusiner S.B. Glycosylinositol phospholipid anchors of the scrapie and cellular prion proteins contain sialic acid. Biochemistry. 1992;31:5043–5053. doi: 10.1021/bi00136a600. [DOI] [PubMed] [Google Scholar]
- 19.Rudd P.M., Endo T., Colominas C., Groth D., Wheeler S.F., Harvey D.J., Wormald M.R., Serban H., Prusiner S.B., Kobata A., et al. Glycosylation differences between the normal and pathogenic prion protein isoforms. Proc. Natl. Acad. Sci. USA. 1999;96:13044–13049. doi: 10.1073/pnas.96.23.13044. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Endo T., Groth D., Prusiner S.B., Kobata A. Diversity of oligosaccharide structures linked to asparagines of the scrapie prion protein. Biochemistry. 1989;28:8380–8388. doi: 10.1021/bi00447a017. [DOI] [PubMed] [Google Scholar]
- 21.Stimson E., Hope J., Chong A., Burlingame A.L. Site-specific characterization of the N-linked glycans of murine prion protein by high-performance liquid chromatography/electrospray mass spectrometry and exoglycosidase digestions. Biochemistry. 1999;38:4885–4895. doi: 10.1021/bi982330q. [DOI] [PubMed] [Google Scholar]
- 22.Katorcha E., Makarava N., Savtchenko R., D’Azzo A., Baskakov I.V. Sialylation of prion protein controls the rate of prion amplification, the cross-species barrier, the ratio of PrPSc glycoform and prion infectivity. PLoS Pathog. 2014;10:e1004366. doi: 10.1371/journal.ppat.1004366. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Katorcha E., Klimova N., Makarava N., Savtchenko R., Pan X., Annunziata I., Takahashi K., Miyagi T., Pshezhetsky A.V., d’Azzo A., et al. Knocking out of cellular neuraminidases Neu1, Neu3 or Neu4 does not affect sialylation status of the prion protein. PLoS ONE. 2015;10:e0143218. doi: 10.1371/journal.pone.0143218. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Wille H., Michelitsch M.D., Guenebaut V., Supattapone S., Serban A., Cohen F.E., Agard D.A., Prusiner S.B. Structural studies of the scrapie prion protein by electron crystallography. Proc. Acad. Natl. Sci. USA. 2002;99:3563–3568. doi: 10.1073/pnas.052703499. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Govaerts C., Wille H., Prusiner S.B., Cohen F.E. Evidance for assembly of prions with left-handed b-helices into trimers. Proc. Acad. Natl. Sci. USA. 2004;101:8342–8347. doi: 10.1073/pnas.0402254101. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Requena J.R., Wille H. The Structure of the infectious prion protein: Experimental data and molecular models. Prion. 2014;8:60–66. doi: 10.4161/pri.28368. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Makarava N., Kovacs G.G., Savtchenko R., Alexeeva I., Ostapchenko V.G., Budka H., Rohwer R.G., Baskakov I.V. A New Mechanism for Transmissible Prion Diseases. J. Neurosci. 2012;32:7345–7355. doi: 10.1523/JNEUROSCI.6351-11.2012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Makarava N., Savtchenko R., Baskakov I.V. Two alternative pathways for generating transmissible prion disease de novo. Acta Neuropathol. Commun. 2015;3:69. doi: 10.1186/s40478-015-0248-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Katorcha E., Baskakov I.V. Analyses of N-linked glycans of PrPSc revealed predominantly 2,6-linked sialic acid residues. FEBS J. 2017;284:3727–3738. doi: 10.1111/febs.14268. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Makarava N., Kovacs G.G., Bocharova O.V., Savtchenko R., Alexeeva I., Budka H., Rohwer R.G., Baskakov I.V. Recombinant prion protein induces a new transmissible prion disease in wild type animals. Acta Neuropathol. 2010;119:177–187. doi: 10.1007/s00401-009-0633-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Tycko R., Savtchenko R., Ostapchenko V.G., Makarava N., Baskakov I.V. The a-Helical C-Terminal Domain of Full-Length Recombinant PrP Converts to an In-Register Parallel á-Sheet Structure in PrP Fibrils: Evidence from Solid State Nuclear Magnetic Resonance. Biochemistry. 2010;49:9488–9497. doi: 10.1021/bi1013134. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Cobb N.J., Sonnichsen F.D., McHaourab H., Surewicz W. Molecular architecture of human prion protein amyloid: A parallel, in-register b-structure. Proc. Acad. Natl. Sci. USA. 2007;104:18946–18951. doi: 10.1073/pnas.0706522104. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Groveman B.R., Dolan M.A., Taubner L.M., Kraus A., Wickner R.B., Caughey B. Parallel in-register intermolecular β-sheet architectures for prion-seeded prion protein (PrP) amyloids. J. Biol. Chem. 2014;289:24129–24142. doi: 10.1074/jbc.M114.578344. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Varquez-Fernandez E., Vos M.R., Afanasyev P., Cebey L., Sevillano A.M., Vidal E., Rosa I., Renault L., Ramos A., Peters P.J., et al. The Structural Architecture of an Infectious Mammalian Prion Using Electron Cryomicroscopy. PLoS Pathog. 2016;12:e1005835. doi: 10.1371/journal.ppat.1005835. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Baskakov I.V., Katorcha E. Multifaceted role of sialylation in prion diseases. Front. Neurosci. 2016;10:358. doi: 10.3389/fnins.2016.00358. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Lawson V.A., Collins S.J., Masters C.L., Hill A.F. Prion protein glycosylation. J. Neurochem. 2005;93:793–801. doi: 10.1111/j.1471-4159.2005.03104.x. [DOI] [PubMed] [Google Scholar]
- 37.Katorcha E., Makarava N., Savtchenko R., Baskakov I.V. Sialylation of the prion protein glycans controls prion replication rate and glycoform ratio. Sci. Rep. 2015;5:16912. doi: 10.1038/srep16912. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Srivastava S., Makarava N., Katorcha E., Savtchenko R., Brossmer R., Baskakov I.V. Post-conversion sialylation of prions in lymphoid tissues. Proc. Acad. Natl. Sci. USA. 2015;112:E6654–E6662. doi: 10.1073/pnas.1517993112. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Katorcha I.V., Katorcha E. Analysis of Covalent Modifications of Amyloidogenic Proteins Using Two-Dimensional Electrophoresis: Prion Protein and Its Sialylation. Methods Mol. Biol. 2018;1779:241–255. doi: 10.1007/978-1-4939-7816-8_15. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Makarava N., Kovacs G.G., Savtchenko R., Alexeeva I., Budka H., Rohwer R.G., Baskakov I.V. Genesis of mammalian prions: From non-infectious amyloid fibrils to a transmissible prion disease. PLoS Pathog. 2011;7:e1002419. doi: 10.1371/journal.ppat.1002419. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Nishina K., Deleault N.R., Mahal S., Baskakov I., Luhrs T., Riek R., Supattapone S. The Stoichiometry of Host PrPC Glycoforms Modulates the Efficiency of PrPSc formation in vitro. Biochemistry. 2006;45:14129–14139. doi: 10.1021/bi061526k. [DOI] [PubMed] [Google Scholar]
- 42.Piro J.R., Harris B.T., Nishina K., Soto C., Morales R., Rees J.R., Supattapone S. Prion Protein Glycosylation Is Not Requiered for Strain-Specific Neurotropism. J. Virol. 2009;83:5321–5328. doi: 10.1128/JVI.02502-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Cancellotti E., Mahal S.P., Somerville R., Diack A., Brown D., Piccardo P., Weissmann C., Manson J.C. Post-translational changes to PrP alter transmissible spongiform encephalopathy strain properties. EMBO J. 2013;32:756–769. doi: 10.1038/emboj.2013.6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Wiseman F.K., Cancellotti E., Piccardo P., Iremonger K., Boyle A., Brown D., Ironside J.W., Manson J.C., Diack A.B. The glycosylation status of PrPC is a key factor in determining transmissible spongiform encephalopathy transmission between species. J. Virol. 2015;89:4738–4747. doi: 10.1128/JVI.02296-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Stura E.A., Muller B.H., Bossus M., Michel S., Jolivet-Reynaud C., Ducancel F. Crystal structure of human prostate-specific antigen in a sandwich antibody complex. J. Mol. Biol. 2011;414:530–544. doi: 10.1016/j.jmb.2011.10.007. [DOI] [PubMed] [Google Scholar]
- 46.Rabinovich G.A., Croci D.O. Regulatori Circuits Mediated by Lectin-Glycan Interaction in Autoimmunity and Cancer. Immunity. 2012;36:322–335. doi: 10.1016/j.immuni.2012.03.004. [DOI] [PubMed] [Google Scholar]
- 47.Linnartz B., Bodea L.-G., Neumann H. Microglia carbohydrate-binding receptors for neural repair. Cell Tissue Res. 2012;349:215–227. doi: 10.1007/s00441-012-1342-7. [DOI] [PubMed] [Google Scholar]
- 48.Varki A. Sialic acids in human health and disease. Trends Mol. Med. 2008;14:351–360. doi: 10.1016/j.molmed.2008.06.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Brown G.C., Neher J.J. Microglial phagocytosis of live neurons. Nat. Rev. Neurosci. 2014;15:209–216. doi: 10.1038/nrn3710. [DOI] [PubMed] [Google Scholar]
- 50.Aminoff D., Bruegge W.F., Bell W.C., Sarpolis K., Williams R. Role of sialic acid in survival of erythrocytes in the circulation: Interaction of neuraminidase-treated and untreated erythrocytes with spleen and liver at the cellular level. Proc. Acad. Natl. Sci. USA. 1977;74:1521–1524. doi: 10.1073/pnas.74.4.1521. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Jansen A.J.G., Josefsson E.C., Rumjantseva V., Liu Q.P., Falet H., Bergmeier W., Cifuni S., Sackstein R., von Andrian U.H., Wagner D.D., et al. Desialylation accelerates platelet clearance after refrigeration and initiates GPIba metalloproteinase-mediated cleavage in mice. Blood. 2012;119:1263–1273. doi: 10.1182/blood-2011-05-355628. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Linnartz B., Kopatz J., Tenner A.J., Neumann H. Sialic acid on the neuronal glycocalyx prevents complement C1 binding and complement receptor-3-mediated removal by microglia. J. Neurosci. 2012;32:946–952. doi: 10.1523/JNEUROSCI.3830-11.2012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Linnartz-Gerlach B., Mathews M., Neumann H. Sensing the neuronal glycocalyx by glial sialic acid binding immunoglobulin-like lectins. Neuroscience. 2014;275:113–124. doi: 10.1016/j.neuroscience.2014.05.061. [DOI] [PubMed] [Google Scholar]
- 54.Linnartz-Gerlach B., Schuy C., Shahraz A., Tenner A.J., Neumann H. Sialylation of neurites inhibits complement-mediated macrophage removal in a human macrophage-neuron Co-Culture System. Glia. 2016;64:35–47. doi: 10.1002/glia.22901. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Katorcha E., Daus M.L., Gonzalez-Montalban N., Makarava N., Lasch P., Beekes M., Baskakov I.V. Reversible off and on switching of prion infectivity via removing and reinstalling prion sialylation. Sci. Rep. 2016;6:33119. doi: 10.1038/srep33119. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Srivastava S., Katorcha E., Daus M.L., Lasch P., Beekes M., Baskakov I.V. Sialylation controls prion fate in vivo. J. Biol. Chem. 2017;292:2359–2368. doi: 10.1074/jbc.M116.768010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Castro-Seoane R., Hummerich H., Sweeting T., Tattum M.H., Linehan J.M., Fernandez de Marco M., Brandner S., Collinge J., Klohn P.C. Plasmacytoid dendritic cells sequester high prion titres at early stages of prion infection. PLoS Pathog. 2012;8:e1002538. doi: 10.1371/journal.ppat.1002538. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Michel B., Meyerett-Reid C., Johnson T., Ferguson A., Wyckoff C., Pulford B., Bender H., Avery A., Telling G., Dow S., et al. Incunabular Imminological Events in Prion Trafficing. Sci. Rep. 2012;2:440. doi: 10.1038/srep00440. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.McCulloch L., Brown K.L., Bradford B.M., Hopkins J., Bailey M., Rajewsky K., Manson J.C., Mabbott N.A. Follicular dendritic cell-specific prion protein (PrP) expression alone is sufficient to sustain prion infection in the spleen. PLoS Pathog. 2011;7:e1002402. doi: 10.1371/journal.ppat.1002402. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Kujala P., Raymond C.R., Romeijn M., Godsave S.F., van Kasteren S.I., Wille H., Prusiner S.B., Mabbott N.A., Peters P.J. Prion Uptake in the Gut: Identification of the First Uptake and Replication Sites. PLoS Pathog. 2011;7:e1002449. doi: 10.1371/journal.ppat.1002449. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Brown K.L., Stewart K., Ritchie D.L., Mabbott N.A., Williams A., Fraser H., Morrison W.I., Bruce M.E. Scrapie replication in lyphoid tissues depends on prion protein-expressing follicular dendritic cells. Nat. Med. 1999;5:1308–1312. doi: 10.1038/15264. [DOI] [PubMed] [Google Scholar]
- 62.Montrasio F., Frigg R., Glatzel M., Klein M.A., Mackay F., Aguzzi A., Weissmann C. Impaired prion replication in spleens of mice lacking functional follicular dendritic cells. Science. 2000;288:1257–1259. doi: 10.1126/science.288.5469.1257. [DOI] [PubMed] [Google Scholar]
- 63.Mabbott N.A., Mackay F., Minns F., Bruce M.E. Temporal inactivation of follicular dendritic cells delays neuroinvasion of scrapie. Nat. Med. 2000;6:719–720. doi: 10.1038/77401. [DOI] [PubMed] [Google Scholar]
- 64.Prinz M., Heikenwalder M., Junt T., Schwarz P., Glatzel M., Heppner F.L., Fu Y.X., Lipp M., Aguzzi A. Positioning of follicular dendritic cells within the spleen controls prion neuroinvasion. Nature. 2003;425:957–962. doi: 10.1038/nature02072. [DOI] [PubMed] [Google Scholar]
- 65.Srivastava S., Katorcha E., Makarava N., Barrett J.P., Loane D.J., Baskakov I.V. Inflammatory response of microglia to prions is controlled by sialylation of PrPSc. Sci. Rep. 2018;8:e11326. doi: 10.1038/s41598-018-29720-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Kovacs G.G., Makarava N., Savtchenko R., Baskakov I.V. Atypical and classical forms of the disease-associated state of the prion protein exhibit distinct neuronal tropism, deposition patterns, and lesion profiles. Am. J. Pathol. 2013;183:1539–1547. doi: 10.1016/j.ajpath.2013.07.024. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Makarava N., Savtchenko R., Alexeeva I., Rohwer R.G., Baskakov I.V. New Molecular Insight into Mechanism of Evolution of Mammalian Synthetic Prions. Am. J. Pathol. 2016;186:1006–1014. doi: 10.1016/j.ajpath.2015.11.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Makarava N., Savtchenko R., Baskakov I.V. Selective amplification of classical and atypical prions using modified protein misfolding cyclic amplification. J. Biol. Chem. 2013;288:33–41. doi: 10.1074/jbc.M112.419531. [DOI] [PMC free article] [PubMed] [Google Scholar]